P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2016-10, Vol.11 (10), p.S242-S243
Main Authors: Herbst, Roy S., Baas, Paul, Perez-Gracia, Jose L., Felip, Enriqueta, Kim, Dong-Wan, Han, Ji-Youn, Molina, Julian, Kim, Joo-Hang, Arvis, Catherine Dubos, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary Jo, Surmont, Veerle, De Castro, Gilberto, Garrido, Marcelo, Shentu, Yue, Dolled-Filhart, Marisa, Im, Ellie, Garon, Edward B.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page S243
container_issue 10
container_start_page S242
container_title Journal of thoracic oncology
container_volume 11
creator Herbst, Roy S.
Baas, Paul
Perez-Gracia, Jose L.
Felip, Enriqueta
Kim, Dong-Wan
Han, Ji-Youn
Molina, Julian
Kim, Joo-Hang
Arvis, Catherine Dubos
Ahn, Myung-Ju
Majem, Margarita
Fidler, Mary Jo
Surmont, Veerle
De Castro, Gilberto
Garrido, Marcelo
Shentu, Yue
Dolled-Filhart, Marisa
Im, Ellie
Garon, Edward B.
description
doi_str_mv 10.1016/j.jtho.2016.08.112
format article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_27676575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086416308218</els_id><sourcerecordid>S1556086416308218</sourcerecordid><originalsourceid>FETCH-LOGICAL-e765-98f2338adf4b920eaa66bbc2901f2ac3c7d5923fb82706b3a08b6a6f5333e1103</originalsourceid><addsrcrecordid>eNo1kc2O0zAUhS0EYoaBF2CBvBwWCf5JHLdiU7UFRlSdSpMNK8txbtSUuI7spNB5mnkGHoEnw1GH1T2Lcz-dew9C7ylJKaHi0yE9DHuXsqhTIlNK2Qt0TfNcJJRL8vJZEymyK_QmhAMhWU4y-RpdsUIUIi_ya_Rnx9KM4lvdBYd7DwGOA9RYB7xb0ZSIj3O8A1t517WPo9UVPgW8cgYG_Rs63DiPdx5OrRtDd8alBz1tbx-WmyW-_b7-sb0v1wmhJGIW3uzbk-4mwhZ-4XK0zv99etC27yBcUKtkQ_EiBAjBxiDzSNTm5xzfWTse3bAHr_vzW_SqiXHh3fO8QeWXdbn8lmzuv94tF5sE4m3JTDaMc6nrJqtmjIDWQlSVYTNCG6YNN0WdzxhvKskKIiquiayEFk3OOQdKCb9BHy7Yfqws1Kr3rdX-rP7_Lho-XwwQQ5xa8CqYFo4G6taDGVTtWkWJmqpSBzVVpaaqFJEqVsX_AUeGhZ4</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy</title><source>ScienceDirect</source><creator>Herbst, Roy S. ; Baas, Paul ; Perez-Gracia, Jose L. ; Felip, Enriqueta ; Kim, Dong-Wan ; Han, Ji-Youn ; Molina, Julian ; Kim, Joo-Hang ; Arvis, Catherine Dubos ; Ahn, Myung-Ju ; Majem, Margarita ; Fidler, Mary Jo ; Surmont, Veerle ; De Castro, Gilberto ; Garrido, Marcelo ; Shentu, Yue ; Dolled-Filhart, Marisa ; Im, Ellie ; Garon, Edward B.</creator><creatorcontrib>Herbst, Roy S. ; Baas, Paul ; Perez-Gracia, Jose L. ; Felip, Enriqueta ; Kim, Dong-Wan ; Han, Ji-Youn ; Molina, Julian ; Kim, Joo-Hang ; Arvis, Catherine Dubos ; Ahn, Myung-Ju ; Majem, Margarita ; Fidler, Mary Jo ; Surmont, Veerle ; De Castro, Gilberto ; Garrido, Marcelo ; Shentu, Yue ; Dolled-Filhart, Marisa ; Im, Ellie ; Garon, Edward B.</creatorcontrib><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1016/j.jtho.2016.08.112</identifier><identifier>PMID: 27676575</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S242-S243</ispartof><rights>2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1556086416308218$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3535,27903,27904,45759</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27676575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herbst, Roy S.</creatorcontrib><creatorcontrib>Baas, Paul</creatorcontrib><creatorcontrib>Perez-Gracia, Jose L.</creatorcontrib><creatorcontrib>Felip, Enriqueta</creatorcontrib><creatorcontrib>Kim, Dong-Wan</creatorcontrib><creatorcontrib>Han, Ji-Youn</creatorcontrib><creatorcontrib>Molina, Julian</creatorcontrib><creatorcontrib>Kim, Joo-Hang</creatorcontrib><creatorcontrib>Arvis, Catherine Dubos</creatorcontrib><creatorcontrib>Ahn, Myung-Ju</creatorcontrib><creatorcontrib>Majem, Margarita</creatorcontrib><creatorcontrib>Fidler, Mary Jo</creatorcontrib><creatorcontrib>Surmont, Veerle</creatorcontrib><creatorcontrib>De Castro, Gilberto</creatorcontrib><creatorcontrib>Garrido, Marcelo</creatorcontrib><creatorcontrib>Shentu, Yue</creatorcontrib><creatorcontrib>Dolled-Filhart, Marisa</creatorcontrib><creatorcontrib>Im, Ellie</creatorcontrib><creatorcontrib>Garon, Edward B.</creatorcontrib><title>P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo1kc2O0zAUhS0EYoaBF2CBvBwWCf5JHLdiU7UFRlSdSpMNK8txbtSUuI7spNB5mnkGHoEnw1GH1T2Lcz-dew9C7ylJKaHi0yE9DHuXsqhTIlNK2Qt0TfNcJJRL8vJZEymyK_QmhAMhWU4y-RpdsUIUIi_ya_Rnx9KM4lvdBYd7DwGOA9RYB7xb0ZSIj3O8A1t517WPo9UVPgW8cgYG_Rs63DiPdx5OrRtDd8alBz1tbx-WmyW-_b7-sb0v1wmhJGIW3uzbk-4mwhZ-4XK0zv99etC27yBcUKtkQ_EiBAjBxiDzSNTm5xzfWTse3bAHr_vzW_SqiXHh3fO8QeWXdbn8lmzuv94tF5sE4m3JTDaMc6nrJqtmjIDWQlSVYTNCG6YNN0WdzxhvKskKIiquiayEFk3OOQdKCb9BHy7Yfqws1Kr3rdX-rP7_Lho-XwwQQ5xa8CqYFo4G6taDGVTtWkWJmqpSBzVVpaaqFJEqVsX_AUeGhZ4</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Herbst, Roy S.</creator><creator>Baas, Paul</creator><creator>Perez-Gracia, Jose L.</creator><creator>Felip, Enriqueta</creator><creator>Kim, Dong-Wan</creator><creator>Han, Ji-Youn</creator><creator>Molina, Julian</creator><creator>Kim, Joo-Hang</creator><creator>Arvis, Catherine Dubos</creator><creator>Ahn, Myung-Ju</creator><creator>Majem, Margarita</creator><creator>Fidler, Mary Jo</creator><creator>Surmont, Veerle</creator><creator>De Castro, Gilberto</creator><creator>Garrido, Marcelo</creator><creator>Shentu, Yue</creator><creator>Dolled-Filhart, Marisa</creator><creator>Im, Ellie</creator><creator>Garon, Edward B.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope></search><sort><creationdate>201610</creationdate><title>P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy</title><author>Herbst, Roy S. ; Baas, Paul ; Perez-Gracia, Jose L. ; Felip, Enriqueta ; Kim, Dong-Wan ; Han, Ji-Youn ; Molina, Julian ; Kim, Joo-Hang ; Arvis, Catherine Dubos ; Ahn, Myung-Ju ; Majem, Margarita ; Fidler, Mary Jo ; Surmont, Veerle ; De Castro, Gilberto ; Garrido, Marcelo ; Shentu, Yue ; Dolled-Filhart, Marisa ; Im, Ellie ; Garon, Edward B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e765-98f2338adf4b920eaa66bbc2901f2ac3c7d5923fb82706b3a08b6a6f5333e1103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herbst, Roy S.</creatorcontrib><creatorcontrib>Baas, Paul</creatorcontrib><creatorcontrib>Perez-Gracia, Jose L.</creatorcontrib><creatorcontrib>Felip, Enriqueta</creatorcontrib><creatorcontrib>Kim, Dong-Wan</creatorcontrib><creatorcontrib>Han, Ji-Youn</creatorcontrib><creatorcontrib>Molina, Julian</creatorcontrib><creatorcontrib>Kim, Joo-Hang</creatorcontrib><creatorcontrib>Arvis, Catherine Dubos</creatorcontrib><creatorcontrib>Ahn, Myung-Ju</creatorcontrib><creatorcontrib>Majem, Margarita</creatorcontrib><creatorcontrib>Fidler, Mary Jo</creatorcontrib><creatorcontrib>Surmont, Veerle</creatorcontrib><creatorcontrib>De Castro, Gilberto</creatorcontrib><creatorcontrib>Garrido, Marcelo</creatorcontrib><creatorcontrib>Shentu, Yue</creatorcontrib><creatorcontrib>Dolled-Filhart, Marisa</creatorcontrib><creatorcontrib>Im, Ellie</creatorcontrib><creatorcontrib>Garon, Edward B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herbst, Roy S.</au><au>Baas, Paul</au><au>Perez-Gracia, Jose L.</au><au>Felip, Enriqueta</au><au>Kim, Dong-Wan</au><au>Han, Ji-Youn</au><au>Molina, Julian</au><au>Kim, Joo-Hang</au><au>Arvis, Catherine Dubos</au><au>Ahn, Myung-Ju</au><au>Majem, Margarita</au><au>Fidler, Mary Jo</au><au>Surmont, Veerle</au><au>De Castro, Gilberto</au><au>Garrido, Marcelo</au><au>Shentu, Yue</au><au>Dolled-Filhart, Marisa</au><au>Im, Ellie</au><au>Garon, Edward B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2016-10</date><risdate>2016</risdate><volume>11</volume><issue>10</issue><spage>S242</spage><epage>S243</epage><pages>S242-S243</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27676575</pmid><doi>10.1016/j.jtho.2016.08.112</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1556-0864
ispartof Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S242-S243
issn 1556-0864
1556-1380
language eng
recordid cdi_pubmed_primary_27676575
source ScienceDirect
title P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T16%3A46%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P2.41%20(also%20presented%20as%20PD1.06):%20Pembrolizumab%20vs%20Docetaxel%20for%20Previously%20Treated%20NSCLC%20(KEYNOTE-010):%20Archival%20vs%20New%20Tumor%C2%A0Samples%20for%20PD-L1%20Assessment:%20Track:%20Immunotherapy&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Herbst,%20Roy%20S.&rft.date=2016-10&rft.volume=11&rft.issue=10&rft.spage=S242&rft.epage=S243&rft.pages=S242-S243&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1016/j.jtho.2016.08.112&rft_dat=%3Celsevier_pubme%3ES1556086416308218%3C/elsevier_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e765-98f2338adf4b920eaa66bbc2901f2ac3c7d5923fb82706b3a08b6a6f5333e1103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/27676575&rfr_iscdi=true